Neumora Therapeutics' depression drug fails to meet main goal of late-stage study (updated)

Neumora Therapeutics

02/01/2025 12:16

(Adds details in paragraphs 2-3)
       Jan 2 (Reuters) - Neumora Therapeutics  NMRA.O  said on
Thursday its experimental  drug to treat depression failed to
meet the main goal of a late-stage study.
    The study, first of the three late-stage trials, was testing
the drug, navacaprant, in patients with major depressive
disorder.
    The drug did not meet the main goal of reducing the symptoms
of the disorder when tested on a scale used to measure the
severity of depressive episodes such as sadness, reduced sleep
and pessimistic thoughts.
    Shares of the company were halted premarket.

 (Reporting by Sriparna Roy and Sneha S K and Kamal Choudhury in
Bengaluru; Editing by Shilpi Majumdar)
 ((Sriparna.Roy@thomsonreuters.com))